CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -192.5%, lower than 95% of its Biotechnology peers (median 6.3%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.43BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-1.24xvs all stocks
52-Week Change
-42.32%vs all stocks
Market Capitalization
11.43BUSDvs all stocks (USD)
Enterprise Value
9.99BUSDvs all stocks (USD)
Forward P/E
-11.02xvs Biotechnology peers
Price to Book (MRQ)
16.83xvs Biotechnology peers
Enterprise to EBITDA
-11.42xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-101.61%vs Biotechnology peers
Return on Equity (TTM)
-192.50%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Aug 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-874.67MUSDvs all stocks (USD)
Net Income (TTM)
-856.09MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-458.43MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-139.68MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-1.09BUSDvs all stocks (USD)
Pre-tax Income
-1.08BUSDFY2025 · Dec 31, 2025Net Income
-1.08BUSDFY2025 · Dec 31, 2025EBIT
-1.08BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-1.09BUSDFY2025 · Dec 31, 2025Research & Development
537.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
556.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-1.44USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.44USDFY2025 · Dec 31, 2025Basic Shares Outstanding
747.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
747.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-1.08BUSDFY2025 · Dec 31, 2025Operating Cash Flow
-336.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
-336.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
225.58MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.08BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
146.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
732.42MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
15.30MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.59MUSDFY2025 · Dec 31, 2025Capital Expenditures
-657.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-484.99MUSDFY2025 · Dec 31, 2025Sale of Investments
311.34MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-174.31MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
604.57MUSDFY2025 · Dec 31, 2025Shares Outstanding
793.12MSharesUpdated Aug 28, 2026Float Shares
152.28MSharesUpdated Aug 28, 2026Shares Short
37.43MSharesUpdated Aug 28, 2026Short Ratio
9.09daysvs all stocks
Short % of Shares Outstanding
23.92%vs all stocks
% Held by Insiders
80.89%vs all stocks
% Held by Institutions
17.36%vs all stocks
Total Cash (MRQ)
690.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.8660USDUpdated Aug 28, 2026Total Debt (MRQ)
20.38MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0324xvs Biotechnology peers
Current Ratio (MRQ)
6.96xvs Biotechnology peers
Book Value per Share (MRQ)
0.7940USDUpdated Aug 28, 2026Total Assets
751.18MUSDvs all stocks (USD)
Total Current Assets
720.30MUSDFY2025 · Dec 31, 2025Total Liabilities
92.32MUSDFY2025 · Dec 31, 2025Total Non-current Assets
30.88MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
19.33MUSDFY2025 · Dec 31, 2025Total Current Liabilities
72.99MUSDFY2025 · Dec 31, 2025Cash
16.37MUSDFY2025 · Dec 31, 2025Cash Equivalents
208.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
225.27MUSDFY2025 · Dec 31, 2025Other Short-term Investments
488.18MUSDFY2025 · Dec 31, 2025Accounts Payable
20.29MUSDFY2025 · Dec 31, 2025Short-term Debt
3.39MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.28MUSDFY2025 · Dec 31, 2025Long-term Debt
17.50MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.83MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.75MUSDFY2025 · Dec 31, 2025Retained Earnings
-2.29BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
658.86MUSDvs all stocks (USD)
52-Week Low
12.07USDUpdated Aug 28, 202652-Week High
29.23USDUpdated Aug 28, 202652-Week Change
-42.32%vs all stocks
Beta
-1.24xvs all stocks
50-Day MA
14.08USDUpdated Aug 28, 2026200-Day MA
16.54USDUpdated Aug 28, 2026Avg 10-Day Volume
6.42MSharesUpdated Aug 28, 2026Avg 30-Day Volume
4.67MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-1.16USDUpdated Aug 28, 2026Other Income / Expense
14.84MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -192.5%, lower than 95% of its Biotechnology peers (median 6.3%)Significant
Return on equity: -1.93Industry median: 0.06Industry P5: -1.60Peers compared: 24.00
Return on assets is -101.6%, lower than 95% of its Biotechnology peers (median 3.6%)Significant
Return on assets: -1.02Industry median: 0.04Industry P5: -0.75Peers compared: 24.00
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 32,166,921.735
Market cap is $11.43B, above the global median of $1.18BNotable
Market cap (USD): 11,431,751,796Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
CSPC Pharmaceutical Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recordati Industria Chimica e Farmaceutica S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Globus Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sichuan Kelun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Halozyme Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Crescent Biopharma, Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
ProKidney Corp
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Yaguang Technology Group Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated